MIGRATORY CHARACTERISTICS OF SKIN-DERIVED NEURAL PRECURSORS AS A NOVEL REGENERATIVE THERAPY FOR ALZHEIMER’S DISEASE
Funder
National Health and Medical Research Council
Funding Amount
$46,945.00
Summary
Memory decline in Alzheimer's disease is linked to a massive loss of neurons and the connections between these cells. Stem cell therapy has the potential to combat this neuronal loss by replenishing the brain with healthy functional neurons. This study aims to develop a new type of neural stem-like cell, termed skin-derived neural precursors, which can be isolated from a patient’s own skin. The outcomes from this work will provide the necessary data for progress into human clinical trial.
Correction Of Friedreich Ataxia Induced Pluripotent Stem Cells By Non-viral Gene Therapy
Funder
National Health and Medical Research Council
Funding Amount
$63,270.00
Summary
Friedreich ataxia (FRDA) is an inherited progressive disorder of the nervous system and heart. Stem cell therapy has the potential to repair or replace damaged tissues and restore organ function in FRDA patients. The defect inherent in stem cells obtained from FRDA patients will be corrected by a gene therapy approach that will restore normal FRDA gene expression and addresses major safety concerns for the clinical use of corrected stem cells in transplantation medicine.
Examining The Specific Vulnerability Of Dopaminergic Cells To Bioenergetic Defects Using Patient-derived Induced Pluripotent Stem Cells As A Model Of Parkinson’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$112,366.00
Summary
The project will develop new cell models of Parkinson's disease utilising the recently discovered technique of inducing pluripotent stem cells from adult skin cells and differentiating them into the type of neurons that are affected in Parkinson's disease. The novel method will allow further insights to be gained into the molecular pathways involved in the disease and facilitate a search for means to rescue these cells from neurodegenerative processes.
Investigating Friedreich Ataxia Cardiomyopathy And Ophthalmopathy Using Induced Pluripotent Stem Cells
Funder
National Health and Medical Research Council
Funding Amount
$136,205.00
Summary
There is no effective treatment for Friedreich ataxia (FRDA). Patients, usually diagnosed as children, will end up in wheelchairs; many have difficulty with movement, speech, develop eye problems and diabetes. Most die at a young age from heart failure. In this project we will study stem cells from patients with FRDA. In the laboratory, these stem cells will be turned into heart and eye cells to study why patients with FRDA develop symptoms and to help develop new drugs to provide effective trea ....There is no effective treatment for Friedreich ataxia (FRDA). Patients, usually diagnosed as children, will end up in wheelchairs; many have difficulty with movement, speech, develop eye problems and diabetes. Most die at a young age from heart failure. In this project we will study stem cells from patients with FRDA. In the laboratory, these stem cells will be turned into heart and eye cells to study why patients with FRDA develop symptoms and to help develop new drugs to provide effective treatment.Read moreRead less
The Menstrual Cycle, Menopause And Gender Specific Health Needs Of Women With Complex Medical And Psychiatric Conditions.
Funder
National Health and Medical Research Council
Funding Amount
$149,982.00
Summary
The great advances in medical science mean that women are living longer, sometimes with very complex conditions.The aim of this study is to determine how common women’s health issues are in women who have had a lung or bone marrow transplant and in women with severe mental illness. The study will involve face to face interview with women and then a survey of a larger number of women. The study will help improve the care and quality of life of women who already face significant health challenges.
CD300f As A Novel Therapeutic Antibody Target In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$89,926.00
Summary
This study aims to develop a new antibody therapy for Acute Myeloid Leukaemia (AML), the most common type of leukaemia in adults. We will study the function of CD300f, a new receptor found on the surface of both healthy blood cells and the cancer cells in AML. We will investigate whether blocking this receptor with a newly developed antibody can be used to kill cancer cells. It is hoped that this study will allow development of this antibody for use in a future clinical trial.
Application Of Adult Stem Cells To Bioengineered Corneal Epithelium And Endothelium Autografts
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
Damage to the cornea causes vision loss. Transplants can restore sight but carry risk of rejection and therefore require anti-rejection therapy, which has side effects. Bioengineered corneal components could replace transplants. Our goals are: 1) Growth of corneal endothelium and epithelium from adult stem cells to reduce the amount of tissue so the patient's own cells could be used. 2) Develop scaffolds that are suitable for implantation or other methods to deliver cells.
Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and l ....Bowel cancer is the 2nd most common cause of cancer death in Australia. Rectal cancer represents 40% of these, and is more common in the elderly who are frequently unable to tolerate chemoradiation therapy. The Mutated in Colorectal Cancer gene (MCC) could become a predictor to chemoradiotherapy in up to 30% of these patients. A defective MCC in tumours can predict a good response to this treatment. Our project will potentially identify patients that are more sensitive to chemoradiotherapy and lead to a personalized treatment of rectal cancer.Read moreRead less
A New Therapeutic Monoclonal Antibody Targeting CD302 In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This project will develop a new antibody treatment for Acute Myeloid Leukaemia. Antibody treatments help the body to attack the leukaemia using its immune system. The prognosis of this leukaemia is poor. Our current treatments use high dose chemotherapy and sometimes a stem cell transplant. Many patients cannot have the current therapy due to their age or other medical problems. A new antibody therapy may be used on its own or with other therapies to help more patients achieve remission.